for people ages 1-21 (full criteria)
at San Francisco, California and other locations
study started
completion around
Principal Investigator
by Arun Rangaswami, MD
Headshot of Arun Rangaswami
Arun Rangaswami



Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

Official Title

An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)


The trial starts with a dose escalation phase. A traditional dose escalation model (3+3) design will be used to determine the recommended phase II dose (RP2D). Subjects will then be treated at the RP2D in the expansion phase of the trial.

Following treatment, tumor response assessments will be performed at Months 1, 3, 6, 9, 12, 18, and 24. At each tumor response assessment visit, imaging will be performed (triphasic CT Scan) and used for response evaluation. Serum AFP levels will also be measured at each tumor response assessment visit.

The active assessment phase of the study will continue for 2 years. Subjects will be followed for 15 years post-treatment for assessment of treatment safety and overall survival.


Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS, Relapsed/Refractory Hepatoblastoma (HB), Pediatric, Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), T-cell therapy, Carcinoma, Neoplasms, Hepatocellular Carcinoma, ET140203 T Cells


You can join if…

Open to people ages 1-21

  1. Histologically confirmed HB, HCN-NOS, or HCC with serum AFP >100ng/mL at the time of screening and following the most recent line of therapy.
  2. Disease reoccurrence after remission following initial standard-of care (SOC) treatment (i.e., relapse) or failure of response to SOC treatment (i.e., refractory).
  3. Age ≥ 1 year and ≤ 21 years.
  4. Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject carries at least one HLA-A2 allele.
  5. Life expectancy of > 4 months per the Investigator's opinion.
  6. Lansky or Karnofsky Performance Scale ≥ 70.
  7. For enrollment to the dose-finding cohort, subjects must have at least one (1) lesion ≥ 5 mm in diameter or two (2) or more lesions ≥ 3 mm in diameter. For the dose-expansion cohort, subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  8. Child-Pugh score of A6 or better.
  9. Adequate organ function.

You CAN'T join if...

  1. Recurrent HB who are candidates for complete surgical resection (e.g., isolated pulmonary relapse amendable to pulmonary metastasectomy).
  2. Pre-existing illness including heart failure, uncontrolled pulmonary disease not cancer-related, or psychiatric illness/social situation that would limit compliance with study requirements.
  3. Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled.
  4. Any known active malignancy (other than HB, HCN-NOS, or HCC).
  5. Pregnant or lactating women.
  6. Received the following within two (2) weeks of leukapheresis or within two (2) weeks of conditioning chemotherapy: cytotoxic chemotherapy, radiation, other anti-cancer therapies (including immunotherapeutic agents), immunosuppressive therapy, or systemic corticosteroids at doses greater than 5 mg/day of prednisone or equivalent doses of other corticosteroids. (Note: Topical and inhaled corticosteroids in standard doses and physiological replacement doses of corticosteroids for adrenal insufficiency are allowed).
  7. Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study.
  8. Contraindication for receipt of conditioning chemotherapeutic agents including Fludarabine and Cyclophosphamide.
  9. Active autoimmune disease requiring systemic immunosuppressive therapy.

    10. Compromised circulation in the main portal vein, hepatic vein, or vena cava due to

    partial or complete obstruction which, in the opinion of the Investigator, would make the subject unsuitable for the study.

    11. History of organ transplant. 12. HB, HCN-NOS, or HCC involving greater than 50% of the liver (volumetric).


  • UCSF Benioff Children's Hospitals accepting new patients
    San Francisco California 94158 United States
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center accepting new patients
    Boston Massachusetts 02215 United States

Lead Scientist at UCSF

  • Arun Rangaswami, MD
    I am one of the senior solid tumor faculty at UCSF, having joined the institution in 2019. My scholarly and clinical practice have focused on the treatment of pediatric liver cancers and rare cancers.


accepting new patients
Start Date
Completion Date
Eureka Therapeutics Inc.
Phase 1/2 research study
Study Type
Expecting 15 study participants
Last Updated